Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Acute Lymphocytic Leukemia
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Leukemia (1940
)
Acute Myelogenous Leukemia (899
)
Chronic Lymphocytic Leukemia (292
)
Chronic Myeloid Leukemia (255
)
B Acute Lymphoblastic Leukemia (163
)
T Acute Lymphoblastic Leukemia (38
)
Childhood B Acute Lymphoblastic Leukemia (37
)
Hairy Cell Leukemia (19
)
Chronic Myelomonocytic Leukemia (18
)
Prolymphocytic Leukemia (16
)
Acute Promyelocytic Leukemia (12
)
Chronic Eosinophilic Leukemia (4
)
Juvenile Myelomonocytic Leukemia (4
)
Chronic Neutrophilic Leukemia (3
)
Leukemia (1940
)
Acute Myelogenous Leukemia (899
)
Chronic Lymphocytic Leukemia (292
)
Chronic Myeloid Leukemia (255
)
B Acute Lymphoblastic Leukemia (163
)
T Acute Lymphoblastic Leukemia (38
)
Childhood B Acute Lymphoblastic Leukemia (37
)
Hairy Cell Leukemia (19
)
Chronic Myelomonocytic Leukemia (18
)
Prolymphocytic Leukemia (16
)
Acute Promyelocytic Leukemia (12
)
Chronic Eosinophilic Leukemia (4
)
Juvenile Myelomonocytic Leukemia (4
)
Chronic Neutrophilic Leukemia (3
)
›
Associations
(388)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
No biomarker
B Acute Lymphoblastic Leukemia
No biomarker
B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: A1 - Approval
tisagenlecleucel-T
Sensitive
:
A1
tisagenlecleucel-T
Sensitive: A1 - Approval
tisagenlecleucel-T
Sensitive
:
A1
No biomarker
Childhood B Acute Lymphoblastic Leukemia
No biomarker
Childhood B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: A1 - Approval
tisagenlecleucel-T
Sensitive
:
A1
tisagenlecleucel-T
Sensitive: A1 - Approval
tisagenlecleucel-T
Sensitive
:
A1
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
C1
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
C1
CD22 positive
B Acute Lymphoblastic Leukemia
CD22 positive
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
ponatinib
Sensitive: A1 - Approval
ponatinib
Sensitive
:
A1
ponatinib
Sensitive: A1 - Approval
ponatinib
Sensitive
:
A1
No biomarker
Acute Lymphocytic Leukemia
No biomarker
Acute Lymphocytic Leukemia
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
No biomarker
B Acute Lymphoblastic Leukemia
No biomarker
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
ponatinib
Sensitive: A1 - Approval
ponatinib
Sensitive
:
A1
ponatinib
Sensitive: A1 - Approval
ponatinib
Sensitive
:
A1
No biomarker
T Acute Lymphoblastic Leukemia
No biomarker
T Acute Lymphoblastic Leukemia
nelarabine
Sensitive: A1 - Approval
nelarabine
Sensitive
:
A1
nelarabine
Sensitive: A1 - Approval
nelarabine
Sensitive
:
A1
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
C1
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
C1
CD19 positive
Acute Lymphocytic Leukemia
CD19 positive
Acute Lymphocytic Leukemia
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
No biomarker
Acute Lymphocytic Leukemia
No biomarker
Acute Lymphocytic Leukemia
mercaptopurine
Sensitive: A1 - Approval
mercaptopurine
Sensitive
:
A1
mercaptopurine
Sensitive: A1 - Approval
mercaptopurine
Sensitive
:
A1
No biomarker
Acute Lymphocytic Leukemia
No biomarker
Acute Lymphocytic Leukemia
vincristine liposomal
Sensitive: A1 - Approval
vincristine liposomal
Sensitive
:
A1
vincristine liposomal
Sensitive: A1 - Approval
vincristine liposomal
Sensitive
:
A1
No biomarker
Childhood B Acute Lymphoblastic Leukemia
No biomarker
Childhood B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
CD19 positive
B Acute Lymphoblastic Leukemia
CD19 positive
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
No biomarker
B Acute Lymphoblastic Leukemia
No biomarker
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
No biomarker
B Acute Lymphoblastic Leukemia
No biomarker
B Acute Lymphoblastic Leukemia
brexucabtagene autoleucel
Sensitive: A1 - Approval
brexucabtagene autoleucel
Sensitive
:
A1
brexucabtagene autoleucel
Sensitive: A1 - Approval
brexucabtagene autoleucel
Sensitive
:
A1
No biomarker
Acute Lymphocytic Leukemia
No biomarker
Acute Lymphocytic Leukemia
recombinant Erwinia asparaginase
Sensitive: A1 - Approval
recombinant Erwinia asparaginase
Sensitive
:
A1
recombinant Erwinia asparaginase
Sensitive: A1 - Approval
recombinant Erwinia asparaginase
Sensitive
:
A1
No biomarker
Acute Lymphocytic Leukemia
No biomarker
Acute Lymphocytic Leukemia
pegaspargase
Sensitive: A1 - Approval
pegaspargase
Sensitive
:
A1
pegaspargase
Sensitive: A1 - Approval
pegaspargase
Sensitive
:
A1
CD20 positive
Childhood B Acute Lymphoblastic Leukemia
CD20 positive
Childhood B Acute Lymphoblastic Leukemia
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
BCR-ABL1 V299L
Acute Lymphocytic Leukemia
BCR-ABL1 V299L
Acute Lymphocytic Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
BCR-ABL1 F317I
Acute Lymphocytic Leukemia
BCR-ABL1 F317I
Acute Lymphocytic Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
nilotinib
Sensitive: A2 - Guideline
nilotinib
Sensitive
:
C1
nilotinib
Sensitive: A2 - Guideline
nilotinib
Sensitive
:
C1
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
bosutinib
Resistant: A2 - Guideline
bosutinib
Resistant
:
A2
bosutinib
Resistant: A2 - Guideline
bosutinib
Resistant
:
A2
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
nilotinib
Resistant: A2 - Guideline
nilotinib
Resistant
:
A2
nilotinib
Resistant: A2 - Guideline
nilotinib
Resistant
:
A2
PDGFRA fusion
Childhood B Acute Lymphoblastic Leukemia
PDGFRA fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
ABL2 fusion
Childhood B Acute Lymphoblastic Leukemia
ABL2 fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
FGFR fusion
Childhood B Acute Lymphoblastic Leukemia
FGFR fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
IL7R mutation
Childhood B Acute Lymphoblastic Leukemia
IL7R mutation
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
SH2B3 alteration
Childhood B Acute Lymphoblastic Leukemia
SH2B3 alteration
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login